Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
West Pharmaceutical Services Inc is a medical instruments & supplies business based in the US. West Pharmaceutical Services shares (WST) are listed on the NYSE and all prices are listed in US Dollars. West Pharmaceutical Services employs 10,065 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $302.37 |
|---|---|
| 52-week range | $275.89 - $474.69 |
| 50-day moving average | $315.86 |
| 200-day moving average | $390.55 |
| Wall St. target price | $386.20 |
| PE ratio | 33.3296 |
| Dividend yield | $0.7 (0.25%) |
| Earnings per share (TTM) | $8.97 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $302.37 from 2022-06-30
| 1 week (2022-06-24) | 0.40% |
|---|---|
| 1 month (2022-06-01) | -2.01% |
| 3 months (2022-03-31) | -26.38% |
| 6 months (2021-12-28) | N/A |
| 1 year (2021-07-01) | -16.70% |
|---|---|
| 2 years (2020-07-01) | 34.39% |
| 3 years (2019-07-01) | 142.42% |
| 5 years (2017-06-30) | 219.90% |
Valuing West Pharmaceutical Services stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of West Pharmaceutical Services's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
West Pharmaceutical Services's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, West Pharmaceutical Services shares trade at around 33x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
West Pharmaceutical Services's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.0503. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into West Pharmaceutical Services's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
West Pharmaceutical Services's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $895.6 million.
The EBITDA is a measure of a West Pharmaceutical Services's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.9 billion |
|---|---|
| Operating margin TTM | 26.83% |
| Gross profit TTM | $1.2 billion |
| Return on assets TTM | 16.01% |
| Return on equity TTM | 32.94% |
| Profit margin | 23.76% |
| Book value | $31.39 |
| Market capitalisation | $22.1 billion |
TTM: trailing 12 months
Dividend payout ratio: 8.13% of net profits
Recently West Pharmaceutical Services has paid out, on average, around 8.13% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.25% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), West Pharmaceutical Services shareholders could enjoy a 0.25% return on their shares, in the form of dividend payments. In West Pharmaceutical Services's case, that would currently equate to about $0.7 per share.
While West Pharmaceutical Services's payout ratio might seem low, this can signify that West Pharmaceutical Services is investing more in its future growth.
West Pharmaceutical Services's most recent dividend payout was on 2 August 2022. The latest dividend was paid out to all shareholders who bought their shares by 18 July 2022 (the "ex-dividend date").
West Pharmaceutical Services's shares were split on a 2:1 basis on 26 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your West Pharmaceutical Services shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for West Pharmaceutical Services shares which in turn could have impacted West Pharmaceutical Services's share price.
Over the last 12 months, West Pharmaceutical Services's shares have ranged in value from as little as $275.89 up to $474.6883. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while West Pharmaceutical Services's is 1.1751. This would suggest that West Pharmaceutical Services's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.